Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of salvianolic acid A to preparation of hyperuricaemia and gout resisting drugs

A technology for hyperuricemia and uric acid, applied in the field of medicine, can solve unreported problems and achieve the effects of reducing serum uric acid levels, treatment prevention and treatment safety, and reducing mRNA expression levels

Pending Publication Date: 2019-05-07
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But its role in the preparation of anti-hyperuricemia and / or anti-gout drugs and / or health products has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of salvianolic acid A to preparation of hyperuricaemia and gout resisting drugs
  • Application of salvianolic acid A to preparation of hyperuricaemia and gout resisting drugs
  • Application of salvianolic acid A to preparation of hyperuricaemia and gout resisting drugs

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0035] Experimental example 1. Salvianolic acid A reduces serum uric acid (UA) level in hyperuricemia model mice.

[0036]Experimental materials: Kunming mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. Potassium oxonate, salvianolic acid A, allopurinol, and benzbromarone were purchased from Sigma-Aldrich, Germany. Sodium carboxymethyl cellulose was purchased from Sinopharm Chemical Reagent Co., Ltd. The uric acid kit was purchased from Zhongsheng Beikong Biotechnology Co., Ltd.

[0037] Solution preparation: 1% sodium carboxymethylcellulose was dissolved, boiled, cooled and used as a solvent to dissolve salvianolic acid A, potassium oxonate, allopurinol and benzbromarone respectively to form a suspension.

[0038] Experimental grouping: 18-20g mice were randomly divided into normal control group, model group, benzbromarone group (25mg·kg -1 , positive control), salvianolic acid A low, medium and high dose groups (3, 10, 30 mg·kg -1 ), 10 in each group. ...

Embodiment 2

[0044] Example 2. Effect of salvianolic acid A on the mRNA expression level of urate anion transporter 1 (URAT1) in hyperuricemia model mice. n=3.

[0045] Experimental grouping: 18-20g mice were randomly divided into normal control group, model group, allopurinol group (25mg·kg -1 , positive control), benzbromarone group (25mg·kg -1 , positive control), salvianolic acid A low, medium and high dose groups (3, 10, 30 mg·kg -1 ), 10 in each group. The relevant solution preparation and experimental scheme are the same as in Example 1. The reverse transcription kit and SYBR green dye were purchased from Biotech Co., Ltd. (TAKARA, Japan). Primers were purchased from Sangon Bioengineering Co., Ltd., and the purification method was HAP.

[0046] Table 2. URAT1 primers and internal reference primer sequences.

[0047]

[0048] After the mice were sacrificed, the kidneys of the mice were taken, and the total RNA in the kidneys was extracted using the Trizol method, and the RN...

Embodiment 3

[0053] Example 3. Effect of salvianolic acid A on the mRNA expression level of glucose transporter 9 (GLUT9) in hyperuricemia model mice. ( n=3).

[0054] Experimental grouping: 18-20g mice were randomly divided into normal control group, model group, benzbromarone group (25mg·kg -1 , positive control), salvianolic acid A low, medium and high dose groups (3, 10, 30 mg·kg -1 ), 10 in each group. The relevant solution preparation and experimental scheme are the same as in Example 2. The reverse transcription kit and SYBR green dye were purchased from Biotech Co., Ltd. (TAKARA, Japan). Primers were purchased from Sangon Bioengineering Co., Ltd., and the purification method was HAP.

[0055] Table 4. GLUT9 primers and internal reference primer sequences.

[0056]

[0057] After the mice were sacrificed, the kidneys of the mice were taken, and the total RNA in the kidneys was extracted using the Trizol method, and the RNA was quantified with a UV spectrophotometer. SYBRG...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of salvianolic acid A to preparation of hyperuricaemia and gout resisting drugs and / or health care products. Hyperuricaemia comprises primary and secondary hyperuricaemia and adult diseases that uric acid concentration in blood is higher than 420[mu]mol / L (male) and 357[mu]mol / L (female) (determination by a phosphotungstic acid reduction method ), or uric acid concentration in blood is higher than 420[mu]mol / L by a uricase-peroxidase coupling method, caused by various factors, and the gout comprises primary gout and secondary gout. It is found that the salvianolic acid A can notably reduce the serum uric acid level of mice after being taken orally, the expression of URAT1 genes mRNA can be notably improved, and the gene mRNA expression of GLUT9 is reduced. It is indicated that the salvianolic acid A can be used for preparing the hyperuricaemia and / or gout resisting drugs and / or health care products, and a safe, effective and economic active substance is provided for the drugs and / or health care products for preventing and / or treating diseases of hyperuricaemia and / or gout.

Description

technical field [0001] The present invention relates to the new application of salvianolic acid A in the preparation of medicines, mainly relates to the application of salvianolic acid A in the preparation of anti-gout medicines, in particular to the preparation of salvianolic acid A in the preparation of anti-hyperuricemia medicines and / or health care products The application belongs to the field of medical technology. Background technique [0002] Gout is a joint disease caused by crystal formation of monosodium urate deposition, which is directly related to hyperuricemia caused by purine metabolism disorder and / or decreased uric acid excretion. [0003] The latest point of view is that the clinical course of gout includes: (1) hyperuricemia, no uric acid crystals, no gout symptoms; (2) observed uric acid crystals or stones, no gout symptoms; (3) deposition of uric acid crystals in the body, acute gout Attack or history of attack; (4) Severe gout, with tophi formation, re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61P19/06
Inventor 杜冠华周启蒙杨海光王海港赵晓悦宋俊科方莲花
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com